The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the international Phase I/II ARROW trial, led by researchers at The University of Texas MD Anderson Cancer Center.
- Berkeley Lab science snapshots
- New treatment targets found for blinding retinal disease
- KIST finds clue to improve artificial vision for patients with retinitis pigmentosa
- How to boost tips and donations with the dueling preference approach
- UT southwestern levels the playing field for testicular cancer patients